Why the study?
Long-term efficacy and safety remain uncertain in patients with vagally mediated bradyarrhythmias undergoing cardioneuroablation.
Does cardioneuroablation (CNA) improve long-term efficacy and safety in patients with vagally mediated bradyarrhythmias (VMB)?
Does cardioneuroablation (CNA) improve long-term efficacy and safety in patients with vagally mediated bradyarrhythmias (VMB)?
Answers are grounded in this paper and cite their sources.
Evidence on cardioneuroablation for vagally mediated bradyarrhythmias remains limited; leaves open its long-term role pending randomized trials.
Objectives: Long-term efficacy and safety are still uncertain in patients with vagally mediated bradyarrhythmias (VMB) undergoing cardioneuroablation (CNA). Thus, we assessed the outcome of CNA in those patients during long-term follow-up using clinical history in outpatient visits.
No takes yet. Share an insight, caveat, or question.
Güler et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: